Login Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

  • Watchlist

    Keep track of companies that you follow and research.

  • 10 Years of Data

    Full access to our data with predictions and indicators that we calculate daily.

  • Screener

    Full access to our screener with tons of custom values and customizable email notifications.

  • XLS Exports

    Excel export of financials and screeners you define and save.

Subscribe now
Screener Weekly Summary

BioCardia, Inc. BCDA

Healthcare  —  Biotechnology
Cash Flow Champion (3y) Insider Buys (last 12m)
Growth Flags show if company had growth for consecutive years,
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Analyst Commentary Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

BioCardia, Inc. (BCDA) Business Profile

Company Overview

BioCardia, Inc. (NASDAQ: BCDA) is a clinical-stage regenerative medicine company headquartered in San Carlos, California. Founded in 1999, BioCardia specializes in the development of innovative therapies aimed at addressing significant unmet medical needs in cardiovascular and pulmonary diseases. The company was co-founded by Dr. Simon Stertzer, a pioneer in interventional cardiology, and has since been led by a team of experienced professionals in the biotechnology and medical device industries. The current CEO and President, Dr. Peter Altman, has been instrumental in driving the company’s strategic vision and advancing its clinical programs.

BioCardia’s mission is to improve the quality of life for patients suffering from chronic and debilitating conditions by leveraging its proprietary biotherapeutic and delivery platforms. The company operates with a strong focus on innovation, clinical excellence, and patient-centric solutions.

Core Business Segments

BioCardia operates primarily in the regenerative medicine space, with a focus on developing cell-based therapies and delivery systems. The company’s core business segments include:

1. Therapeutic Development

  • CardiAMP Cell Therapy System: This is BioCardia’s flagship product, designed to treat ischemic heart failure and chronic myocardial ischemia. The CardiAMP system uses autologous bone marrow-derived cells to stimulate the body’s natural healing processes. It is currently in pivotal Phase III clinical trials.
  • CardiALLO Cell Therapy System: This allogeneic cell therapy product is aimed at patients who are not eligible for the CardiAMP system. It uses donor-derived mesenchymal stem cells and is in early-stage clinical development.

2. Delivery Systems

  • Helix Biotherapeutic Delivery System: A proprietary catheter-based system designed to deliver therapeutic agents directly to the heart muscle. This system ensures precise and efficient delivery, minimizing risks and maximizing therapeutic outcomes.
  • Morph Universal Catheter System: A versatile catheter platform used for various cardiovascular interventions, including the delivery of cell therapies and other biologics.

3. Pipeline Expansion

  • BioCardia is actively exploring additional indications for its cell therapy platforms, including pulmonary diseases and other chronic conditions. The company is also investigating the potential of its delivery systems for use in non-cardiovascular applications.

Business Model

BioCardia’s business model is centered around the integration of its proprietary therapeutic and delivery platforms. The company generates revenue through:

  • Product Sales: Revenue from the sale of its delivery systems, including the Helix and Morph catheters.
  • Clinical Trial Partnerships: Collaborations with academic institutions and healthcare organizations to advance clinical research.
  • Licensing Agreements: Licensing its proprietary technologies to other biotech and pharmaceutical companies.
  • Future Commercialization: Upon regulatory approval, BioCardia plans to commercialize its CardiAMP and CardiALLO therapies, targeting large patient populations with unmet medical needs.

The company’s vertically integrated approach allows it to control the entire value chain, from product development to clinical implementation, ensuring high-quality outcomes and cost efficiency.

Strategic Direction

BioCardia is committed to advancing its clinical programs and expanding its therapeutic portfolio. Key strategic priorities include:

  • Regulatory Approvals: Securing FDA approval for the CardiAMP and CardiALLO systems to enable commercialization.
  • Pipeline Diversification: Exploring new indications for its cell therapy platforms, including chronic obstructive pulmonary disease (COPD) and other pulmonary conditions.
  • Global Expansion: Establishing a presence in international markets through strategic partnerships and licensing agreements.
  • Sustainability Goals: Incorporating environmentally sustainable practices in its manufacturing and supply chain operations.
  • Technological Innovation: Investing in research and development to enhance the efficacy and safety of its therapies and delivery systems.

Competitive Landscape

BioCardia operates in a highly competitive and rapidly evolving industry. Key competitors include:

  • Mesoblast Limited: A leader in allogeneic cell therapy with a focus on cardiovascular and inflammatory diseases.
  • Vericel Corporation: Specializes in autologous cell therapies for sports medicine and severe burn care.
  • Celyad Oncology: Develops CAR-T cell therapies for cancer and other indications.
  • Athersys, Inc.: Focused on regenerative medicine with its MultiStem cell therapy platform.

BioCardia differentiates itself through its proprietary delivery systems, which provide a competitive edge in terms of precision and efficacy.

Risk Factors

BioCardia faces several risks that could impact its operations and financial performance:

  • Regulatory Challenges: Delays or failures in obtaining FDA or international regulatory approvals could hinder commercialization efforts.
  • Market Dependence: The company’s success is heavily reliant on the adoption of its CardiAMP and CardiALLO therapies.
  • Supply Chain Disruptions: Dependence on third-party suppliers for raw materials and components poses a risk of supply chain interruptions.
  • Clinical Trial Risks: Unfavorable trial outcomes or safety concerns could negatively affect product development timelines.
  • Competitive Pressure: Intense competition from established players and emerging startups could limit market share.

Recent Developments

  • Clinical Trial Progress: BioCardia recently announced positive interim results from its Phase III CardiAMP Heart Failure Trial, demonstrating significant improvements in patient outcomes.
  • Partnerships: The company entered into a collaboration with a leading academic institution to explore new applications for its delivery systems.
  • Technological Advancements: BioCardia unveiled an upgraded version of its Helix Biotherapeutic Delivery System, featuring enhanced precision and ease of use.
  • COVID-19 Impact: The pandemic caused temporary delays in clinical trials but also highlighted the potential of regenerative medicine in addressing respiratory complications.

Investment Considerations

Strengths:

  • Proprietary technologies with strong intellectual property protection.
  • Advanced clinical pipeline targeting large and underserved markets.
  • Experienced leadership team with a proven track record.
  • Vertically integrated business model ensuring quality and cost efficiency.

Risks:

  • Dependence on successful clinical trial outcomes and regulatory approvals.
  • High competition in the regenerative medicine space.
  • Financial risks associated with being a clinical-stage company.

Conclusion

BioCardia, Inc. is well-positioned to become a leader in regenerative medicine, with its innovative therapies and delivery systems addressing critical unmet needs in cardiovascular and pulmonary diseases. While the company faces challenges typical of a clinical-stage biotech firm, its strong pipeline, proprietary technologies, and strategic vision provide a solid foundation for future growth. Investors should weigh the potential rewards against the inherent risks, keeping an eye on upcoming clinical milestones and regulatory developments.